Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

NCT01650090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Relapse of Osteosarcoma

Interventions

DRUG: Inhaled Lipid Cisplatin (ILC)

Sponsor

Eleison Pharmaceuticals LLC.